Methods and compounds for treating effects of COVID-19 disease

A method for treating effects of COVID-19 disease in a patient, comprising:

• obtaining an ashwagandha (Withania somnifera) extract from a first instance of a hydroglycolic extraction process applied to an ashwagandha plant;
• obtaining a shallaki (Boswellia serrata) extract from a second instance of the hydroglycolic extraction process applied to a shallaki plant;
• obtaining a ginger (Zingiber officinale) extract from a third instance of the hydroglycolic extraction process applied to a ginger plant;
• obtaining a turmeric extract (Curcuma longa) from a fourth instance of the hydroglycolic extraction process applied to a turmeric plant;
• wherein each instance of the hydroglycolic extraction process for obtaining a respective extract comprises soaking a respective plant material in chloroform and aqueous 60% methanol for 8-12 hours;
• filtering the chloroform and aqueous 60% methanol to obtain a first residue and a first filtrate;
• settling the first filtrate to provide two immiscible layers, wherein the two immiscible layers are an aqueous methanol layer and a chloroform layer;
• separating the chloroform layer;
• concentrating the chloroform layer to obtain a first dry extract of the respective plant material;
• dissolving the first dry extract in hexane;
• filtering the first dry extract dissolved in the hexane to obtain a second residue and second filtrate;
• drying the second residue and storing the second residue as a first fraction;
• re-extracting the first fraction with the hydroglycolic extraction process to obtain a second fraction;
• combining the first and second fractions to provide a pharmacologically active fraction of the respective plant material;
• mixing the pharmacologically active fraction of the ashwagandha extract, the pharmacologically active fraction of the shallaki extract, the pharmacologically active fraction of the ginger extract, and the pharmacologically active fraction of the turmeric extract into a compound comprising, by weight, 5 parts of the pharmacologically active fraction of the ashwagandha extract by weight, 5 parts of the pharmacologically active fraction of the shallaki extract by weight, 4/3 parts of the pharmacologically active fraction of the ginger extract by weight, and 1 part of the pharmacologically active fraction of the turmeric extract by weight;
• and
• orally administering between 500-3600 milligrams of the compound per day to the patient.